Clinical neuropharmacologyHumansMetforminMalePioglitazoneGliclazide
RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.
Steven Lehrer, Peter Rheinstein
Published: 202610.1097/WNF.0000000000000659
Abstract
OBJECTIVES: Metformin is the first-line treatment for type 2 diabetes (T2D), yet interindividual variability in glycemic response remains poorly understood. Preclinical studies demonstrate that low-dose metformin lowers glucose via Rap1 signaling in…
Preview only. Read the full abstract at the source